A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 928)

Abstract

Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), the most common cancer in AIDS patients. All herpesviruses express a conserved dimeric serine protease that is required for generating infectious virions and is therefore of pharmaceutical interest. Given the past challenges of developing drug-like active-site inhibitors to this class of proteases, small-molecules targeting allosteric sites are of great value. In light of evidence supporting a strong structural linkage between the dimer interface and the protease active site, we have focused our efforts on the dimer interface for identifying dimer disrupting inhibitors. Here, we describe a high throughput screening approach for identifying small molecule dimerization inhibitors of KSHV protease. The helical mimetic, small molecule library used, as well as general strategies for selecting compound libraries for this application will also be discussed. This methodology can be applicable to other systems where an alpha helical moiety plays a dominant role at the interaction site of interest, and in vitro assays to monitor function are in place.

Key words

Human herpesvirus protease Kaposi’s sarcoma-associated herpesvirus (KSHV) Dimer disruptor Allosteric inhibitor Fluorogenic enzyme assay Alpha helical mimetic molecules High throughput screening 

Notes

Acknowledgments

This work was supported by NIH grants T32 GMO7810, AIO67423 (C.S.C.), and by the American Lebanese and Syrian Associated Charities and St Jude Children’s Research Hospital (R.K.G.).

References

  1. 1.
    Borthwick AD et al (2002) Design and ­synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality. J Med Chem 45:1–18PubMedCrossRefGoogle Scholar
  2. 2.
    Borthwick AD et al (2002) Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability. Bioorg Med Chem Lett 12:1719–22PubMedCrossRefGoogle Scholar
  3. 3.
    Borthwick AD et al (1998) Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease. Bioorg Med Chem Lett 8:365–70PubMedCrossRefGoogle Scholar
  4. 4.
    Gopalsamy A et al (2004) Design and syntheses of 1,6-naphthalene derivatives as selective HCMV protease inhibitors. J Med Chem 47:1893–9PubMedCrossRefGoogle Scholar
  5. 5.
    Ogilvie W et al (1997) Peptidomimetic inhibitors of the human cytomegalovirus protease. J Med Chem 40:4113–35PubMedCrossRefGoogle Scholar
  6. 6.
    Waxman L, Darke PL (2000) The herpesvirus proteases as targets for antiviral chemotherapy. Antivir Chem Chemother 11:1–22PubMedGoogle Scholar
  7. 7.
    Marnett AB, Nomura AM, Shimba N, Ortiz de Montellano PR, Craik CS (2004) Communication between the active sites and dimer interface of a herpesvirus protease revealed by a transition-state inhibitor. Proc Natl Acad Sci USA 101:6870–5PubMedCrossRefGoogle Scholar
  8. 8.
    Nomura AM, Marnett AB, Shimba N, Dotsch V, Craik CS (2005) Induced structure of a helical switch as a mechanism to regulate enzymatic activity. Nat Struct Mol Biol 12:1019–20PubMedGoogle Scholar
  9. 9.
    Nomura AM, Marnett AB, Shimba N, Dotsch V, Craik CS (2006) One functional switch mediates reversible and irreversible inactivation of a herpesvirus protease. Biochemistry 45:3572–9PubMedCrossRefGoogle Scholar
  10. 10.
    Pray TR, Nomura AM, Pennington MW, Craik CS (1999) Auto-inactivation by cleavage within the dimer interface of Kaposi’s sarcoma-associated herpesvirus protease. J Mol Biol 289:197–203PubMedCrossRefGoogle Scholar
  11. 11.
    Pray TR, Reiling KK, Demirjian BG, Craik CS (2002) Conformational change coupling the dimerization and activation of KSHV protease. Biochemistry 41:1474–82PubMedCrossRefGoogle Scholar
  12. 12.
    Lazic A, Goetz DH, Nomura AM, Marnett AB, Craik CS (2007) Substrate modulation of enzyme activity in the herpesvirus protease family. J Mol Biol 373:913–23PubMedCrossRefGoogle Scholar
  13. 13.
    Reiling KK, Pray TR, Craik CS, Stroud RM (2000) Functional consequences of the Kaposi’s sarcoma-associated herpesvirus protease structure: regulation of activity and dimerization by conserved structural elements. Biochemistry 39:12796–803PubMedCrossRefGoogle Scholar
  14. 14.
    Shimba N, Nomura AM, Marnett AB, Craik CS (2004) Herpesvirus protease inhibition by dimer disruption. J Virol 78:6657–65PubMedCrossRefGoogle Scholar
  15. 15.
    Lee GM, Craik CS (2009) Trapping moving targets with small molecules. Science 324:213–5PubMedCrossRefGoogle Scholar
  16. 16.
    Shahian T et al (2009) Inhibition of a Viral Enzyme by a Small Molecule Dimer Disruptor. Nat Chem Biol 9:640–6CrossRefGoogle Scholar
  17. 17.
    Lu F et al (2006) Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. J Comb Chem 8:315–25PubMedCrossRefGoogle Scholar
  18. 18.
    Cummings CG, Hamilton AD (2010) Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr Opin Chem Biol 14:341–6PubMedCrossRefGoogle Scholar
  19. 19.
    Davis JM, Tsou LK, Hamilton AD (2007) Synthetic non-peptide mimetics of alpha-helices. Chem Soc Rev 36:326–34PubMedCrossRefGoogle Scholar
  20. 20.
    Gavathiotis E et al (2008) BAX activation is initiated at a novel interaction site. Nature 455:1076–81PubMedCrossRefGoogle Scholar
  21. 21.
    Henchey LK, Jochim AL, Arora PS (2008) Contemporary strategies for the stabilization of peptides in the alpha-helical conformation. Curr Opin Chem Biol 12:692–7PubMedCrossRefGoogle Scholar
  22. 22.
    Moellering RE et al (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462:182–8PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4:67–73PubMedCrossRefGoogle Scholar
  24. 24.
    Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK (2005) High-throughput assays for promiscuous inhibitors. Nat Chem Biol 1:146–8PubMedCrossRefGoogle Scholar
  25. 25.
    Feng BY, Shoichet BK (2006) A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc 1:550–3PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of Pharmaceutical ChemistryUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Graduate Group in Biochemistry and Molecular BiologyUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations